PMID- 23892687
OWN - NLM
STAT- MEDLINE
DCOM- 20150122
LR  - 20140403
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 20
IP  - 4
DP  - 2014 May
TI  - Synergistic thrombotic risk of antibodies against phosphatidylserine and 
      prothrombin and beta-2-glycoprotein I.
PG  - 442-7
LID - 10.1177/1076029613497424 [doi]
AB  - BACKGROUND: Coagulation and anticoagulation systems are good targets of 
      antiphospholipid antibodies. We assessed the contribution of the antiphospholipid 
      antibodies to the thrombotic risk. METHODS: Enzyme-linked immunosorbent assays on 
      antibodies against phosphatidylserine and prothrombin (PS/PT), protein C, protein 
      S, protein Z, and thrombomodulin were performed in 164 patients who showed 
      positive results for lupus anticoagulant or anticardiolipin antibody. RESULTS: 
      Anti-beta-2-glycoprotein I (beta2GPI) and anti-PS/PT were significant risk factors for 
      thrombotic events (P < .001, P = .049). However, there was no association between 
      antiprotein C, antiprotein S, antiprotein Z, or antithrombomodulin and 
      thrombosis. Coexistence of anti-beta2GPI and anti-PS/PT antibodies was significantly 
      associated with thrombotic events (P = .001). Interestingly, the absence of both 
      anti-beta2GPI and anti-PS/PT antibodies was a significant preventive factor for 
      thrombosis (P = .003). CONCLUSION: Our data show a lack of association of 
      antiprotein C, antiprotein S, antiprotein Z, and antithrombomodulin antibodies 
      with thrombosis. However, the combination of conventional anti-beta2GPI with 
      anti-PS/PT antibody is expected to enhance the predicting power of thrombotic 
      risk.
FAU - Kim, Hyungsuk
AU  - Kim H
AD  - 1Department of Laboratory Medicine, Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Kim, Ji-Eun
AU  - Kim JE
FAU - Hwang, Sang Mee
AU  - Hwang SM
FAU - Lee, Hye Ryun
AU  - Lee HR
FAU - Han, Kyou-Sup
AU  - Han KS
FAU - Kim, Hyun Kyung
AU  - Kim HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130726
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (Phosphatidylserines)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 9001-26-7 (Prothrombin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Anticardiolipin/blood
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/*blood
MH  - Child
MH  - Humans
MH  - Lupus Coagulation Inhibitor/blood
MH  - Male
MH  - Middle Aged
MH  - Phosphatidylserines/*immunology
MH  - Prothrombin/*immunology
MH  - Risk Factors
MH  - Thrombosis/blood/*immunology
MH  - Young Adult
MH  - beta 2-Glycoprotein I/*immunology
OTO - NOTNLM
OT  - antiphosphatidylserine and prothrombin antibody
OT  - antiphospholipid antibodies
OT  - lupus anticoagulant
OT  - thromboembolism
EDAT- 2013/07/31 06:00
MHDA- 2015/01/23 06:00
CRDT- 2013/07/30 06:00
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2015/01/23 06:00 [medline]
AID - 1076029613497424 [pii]
AID - 10.1177/1076029613497424 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2014 May;20(4):442-7. doi: 10.1177/1076029613497424. 
      Epub 2013 Jul 26.